There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...

Combinations of LABA + LAMA + ICS in separate inhalers are used in patients with asthma and COPD to improve and control symptoms and to reduce exacerbations. The 4-year UPLIFT study provides the ...

Available treatments for COPD are ... the disease 7. Inhaled corticosteroids (ICS), short- and long-acting β 2-agonists (SABA and LABA), long-acting muscarinic antagonists (LAMA) and fixed ...

whereas group B must be given long-acting muscarinic antagonist (LAMA) or a LABA, and groups C and D should take an ICS in combination. In terms of stable COPD management, the most important ...

Inhalers for COPD provide steroids, bronchodilators, or combination drugs. The three types differ in the mechanism by which the medication is inhaled and have different instructions for use.

Further, if initial pharmacotherapy with LABA or LAMA after a COPD exacerbation does not elicit an appropriate patient response and if guideline concordance, inhaler technique, and comorbidities ...

“We are proud to continue advancing our asthma and COPD inhaled drug program, achieving key clinical development milestones on schedule,” said Xian-Ming Zeng, Ph.D., CEO of Transpire Bio.